This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Top line 48-wk results in Q4 2023.
The purpose of the study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Topline data in Q1 2025.
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB).
Top line data readout H1 2024.
910 Clopper Road
Gaithersburg, MD 20878
© 2023 Altimmune Website.
All rights reserved.